177 related articles for article (PubMed ID: 16955399)
1. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer.
Isaacs JT; Pili R; Qian DZ; Dalrymple SL; Garrison JB; Kyprianou N; Björk A; Olsson A; Leanderson T
Prostate; 2006 Dec; 66(16):1768-78. PubMed ID: 16955399
[TBL] [Abstract][Full Text] [Related]
2. Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide.
Vukanovic J; Isaacs JT
Cancer Res; 1995 Aug; 55(16):3517-20. PubMed ID: 7543015
[TBL] [Abstract][Full Text] [Related]
3. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts.
Dalrymple SL; Becker RE; Isaacs JT
Prostate; 2007 May; 67(7):790-7. PubMed ID: 17373719
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents.
Joseph IB; Vukanovic J; Isaacs JT
Cancer Res; 1996 Aug; 56(15):3404-8. PubMed ID: 8758902
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic effects of the quinoline-3-carboxamide linomide.
Vukanovic J; Passaniti A; Hirata T; Traystman RJ; Hartley-Asp B; Isaacs JT
Cancer Res; 1993 Apr; 53(8):1833-7. PubMed ID: 7682157
[TBL] [Abstract][Full Text] [Related]
6. Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers.
Vukanovic J; Isaacs JT
Cancer Res; 1995 Apr; 55(7):1499-504. PubMed ID: 7533663
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050).
Jennbacken K; Welén K; Olsson A; Axelsson B; Törngren M; Damber JE; Leanderson T
Prostate; 2012 Jun; 72(8):913-24. PubMed ID: 22287276
[TBL] [Abstract][Full Text] [Related]
8. The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers.
Ichikawa T; Lamb JC; Christensson PI; Hartley-Asp B; Isaacs JT
Cancer Res; 1992 Jun; 52(11):3022-8. PubMed ID: 1591718
[TBL] [Abstract][Full Text] [Related]
9. Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer.
Bandyopadhyay A; Wang L; López-Casillas F; Mendoza V; Yeh IT; Sun L
Prostate; 2005 Apr; 63(1):81-90. PubMed ID: 15468171
[TBL] [Abstract][Full Text] [Related]
10. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus-mediated interferon-beta gene transfer inhibits angiogenesis in and progression of orthotopic tumors of human prostate cancer cells in nude mice.
Lee J; Wang A; Hu Q; Lu S; Dong Z
Int J Oncol; 2006 Dec; 29(6):1405-12. PubMed ID: 17088978
[TBL] [Abstract][Full Text] [Related]
12. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of tumor angiogenesis by targeting endothelial surface ATP synthase with sangivamycin.
Komi Y; Ohno O; Suzuki Y; Shimamura M; Shimokado K; Umezawa K; Kojima S
Jpn J Clin Oncol; 2007 Nov; 37(11):867-73. PubMed ID: 17956898
[TBL] [Abstract][Full Text] [Related]
14. Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts.
Chen D; Cui QC; Yang H; Barrea RA; Sarkar FH; Sheng S; Yan B; Reddy GP; Dou QP
Cancer Res; 2007 Feb; 67(4):1636-44. PubMed ID: 17308104
[TBL] [Abstract][Full Text] [Related]
15. Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer.
Ischenko I; Guba M; Yezhelyev M; Papyan A; Schmid G; Green T; Fennell M; Jauch KW; Bruns CJ
Angiogenesis; 2007; 10(3):167-82. PubMed ID: 17486419
[TBL] [Abstract][Full Text] [Related]
16. The effect of a novel botanical agent TBS-101 on invasive prostate cancer in animal models.
Evans S; Dizeyi N; Abrahamsson PA; Persson J
Anticancer Res; 2009 Oct; 29(10):3917-24. PubMed ID: 19846929
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of angiogenesis and metastases of the Lewis-lung cell carcinoma by the quinoline-3-carboxamide, Linomide.
Borgström P; Torres Filho IP; Hartley-Asp B
Anticancer Res; 1995; 15(3):719-28. PubMed ID: 7544090
[TBL] [Abstract][Full Text] [Related]
18. Ability of potent vitamin D3 analogs to inhibit growth of prostate cancer cells in vivo.
Vegesna V; O'Kelly J; Said J; Uskokovic M; Binderup L; Koeffle HP
Anticancer Res; 2003; 23(1A):283-9. PubMed ID: 12680225
[TBL] [Abstract][Full Text] [Related]
19. The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature.
Fenton BM; Paoni SF
Cancer Res; 2007 Oct; 67(20):9921-8. PubMed ID: 17942924
[TBL] [Abstract][Full Text] [Related]
20. Tumor anti-angiogenic effect and mechanism of action of delta-tocotrienol.
Shibata A; Nakagawa K; Sookwong P; Tsuzuki T; Oikawa S; Miyazawa T
Biochem Pharmacol; 2008 Aug; 76(3):330-9. PubMed ID: 18599020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
